From: Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Current model | Â | Â | Â | Â | Â | Â |
---|---|---|---|---|---|---|
Treatment sequence | AA | AAwd | Docetaxel | Abiraterone | OtherTx | Â |
% of patients receiving each line of treatment | 100% | 88.1% | 72.7% | 54.2% | 29.4% | Â |
  Mean duration per patient (95%CI)* | 8.5 (8.4-8.6) | 4.3 (4.3-4.4) | 7.1 (7.0-7.1) | 10 (9.9-10.2) | 14.6 (14.3-14.9) |  |
  Median duration per patient (IQR)* | 8 (5–12) | 4 (3–6) | 7 (7–8) | 9 (4–17) | 15 (6–24) |  |
  Mean Survival (95%CI)** | 28.1 (27.7-28.4) | 22.1 (21.7-22.4) | 21.3 (20.9-21.6) | 18.8 (18.4-19.1) | 15.2 (14.9-15.5) |  |
  Median Survival (IQR)** | 25 (14–40) | 19 (7–24) | 18 (9–32) | 16 (8–28) | 16 (7–24) |  |
Alternate model | Â | Â | Â | Â | Â | Â |
Treatment sequence | AA | AAwd | Abiraterone | Docetaxel | Cabazitaxel | OtherTx |
% of patients receiving each line of treatment | 100% | 88.0% | 72.6% | 47.4% | 35.4% | 26.9% |
  Mean duration per patient (95%CI)* | 8.6 (8.5-8.7) | 4.4 (4.3-4.4) | 20.2 (19.9- 20.4) | 7.0 (7.0-7.1) | 5.7 (5.6-5.8) | 15.0 (14.7-15.4) |
  Median duration per patient (IQR)* | 8 (5–12) | 4 (3–6) | 19 (9–35) | 7 (7–8) | 5 (4–7) | 16 (7–24) |
  Mean Survival (95%CI)** | 37.3 (36.8-37.8) | 32.5 (32.0-32.9) | 33.8 (33.4.0-34.3) | 20.4 (20.1-20.8) | 17.6 (17.3-17.9) | 15.7 (15.4-16.0) |
  Median Survival (IQR)** | 34 (15–56) | 30.0 (12–50) | 32 (17–48) | 18 (9–34) | 17 (8–28) | 17 (8–24) |